Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease

Status Recruiting

Clinical Trial Summary

The cognitive impairment of Parkinson's disease is non amnestic, which is characterized by working memory impairment and executive dysfunction. The current drug therapy (such as levodopa, dopamine receptor agonists) and surgical treatment (such as deep brain electrical stimulation, thalamic lesion) not only can not effectively alleviate cognitive impairment, but also may aggravate cognitive and speech behavior abnormalities. This project will explore how dopamine regulates temporal working memory in human research by combining drug intervention, neuroimaging and cognitive tasks.

Clinical Trial Description

Parkinson's disease (PD) is a common neurodegenerative disease in the elderly. The incidence rate of China's disease is 1.7% in the population over 65 years old. The latest research shows that Parkinson's disease is not a simple motor disorder, but a multi organ dysfunction disorder with both motor symptoms and non motor symptoms. With the development of the disease, more than 80% of the PD patients will develop dementia. Different from the amnestic cognitive impairment of Alzheimer's disease, the cognitive impairment of Parkinson's disease is non amnestic, characterized by working memory impairment and executive dysfunction. The current mainstream drug therapy (such as levodopa, dopamine receptor agonists) and surgical treatment (such as deep brain electrical stimulation, thalamic lesion) can not effectively alleviate cognitive impairment, and may even aggravate cognitive and speech behavior abnormalities, We should first understand the neurochemical (molecular) mechanisms of working memory impairment and executive dysfunction in Parkinson's disease. A prospective single blind randomized controlled design was used. Newly diagnosed PD patients were randomly assigned to three treatment groups: Madopar monotherapy group (n = 50), senfrol monotherapy group (n = 50) and placebo group (n = 50). Objective to study the performance of temporal working memory in PD patients and reveal the dopaminergic mechanism of temporal working memory. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04968613
Study type	Interventional
Source	Peking University Third Hospital
Contact	Yingshuang Zhang
Phone	18511650863
Email	zhangys0317@126.com
Status	Recruiting
Phase	Phase 4
Start date	January 1, 2018
Completion date	December 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05415774` - Combined Deep Brain Stimulation in Parkinson's Disease	N/A
Recruiting	`NCT04691661` - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease	Phase 2
Active, not recruiting	`NCT05754086` - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed	`NCT04045925` - Feasibility Study of the Taïso Practice in Parkinson's Disease	N/A
Recruiting	`NCT04194762` - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation	N/A
Completed	`NCT02705755` - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)	Phase 2
Terminated	`NCT03052712` - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies	N/A
Recruiting	`NCT05830253` - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting	`NCT03272230` - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System	N/A
Recruiting	`NCT06139965` - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed	`NCT04580849` - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease	N/A
Completed	`NCT03980418` - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam	N/A
Completed	`NCT04477161` - Effect of Ketone Esters in Parkinson's Disease	N/A
Completed	`NCT04942392` - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic	N/A
Terminated	`NCT03446833` - LFP Beta aDBS Feasibility Study	N/A
Completed	`NCT03497884` - Individualized Precise Localization of rTMS on Primary Motor Area	N/A
Completed	`NCT05538455` - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases	N/A
Recruiting	`NCT04997642` - Parkinson's Disease and Movement Disorders Clinical Database
Completed	`NCT04117737` - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson	N/A
Recruiting	`NCT03618901` - Rock Steady Boxing vs. Sensory Attention Focused Exercise	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.